On January 27, 2026, UnitedHealth Group shares plunged by approximately 19.9%, marking the steepest one‐day percentage loss since April. The sell‐off was driven by a federal proposal to lift Medicare Advantage payment rates by just 0.09%, well below industry expectations, as well as softer revenue guidance for 2026. Intraday trading saw the stock fluctuate between intraday extremes, with total volume reaching 56.14 million shares, signaling heightened investor activity.

In the wake of the downturn, Piper Sandler reiterated its optimistic outlook, assigning a price objective that implies roughly 40.6% upside from current levels. The firm cited UnitedHealth’s leadership across its UnitedHealthcare and Optum segments, ongoing AI‐driven efficiency gains, and a robust market capitalization of about $255.05 billion as justification for expecting a material recovery in the company’s valuation.

UnitedHealth now anticipates a 2% year‐over‐year revenue decline in 2026, reflecting planned enrollment adjustments—forecasting up to 2.8 million fewer covered lives—and enterprise‐wide cost controls. Despite this, operating income is projected to exceed $24 billion, supported by successful efficiency initiatives. However, the minimal increase in Medicare Advantage reimbursement rates has elevated the medical care ratio into the high-88% range, underscoring near‐term margin pressure even as management targets a long‐term adjusted EPS CAGR of 13–16%.